High BCL2 in MCL universal (cyclin D1-driven survival pathway). Venetoclax + ibrutinib (A...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-BCL2-EXPRESSION-MCL |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-MCL |
| Sources | SRC-NCCN-BCELL-2025 |
Actionability Facts
| Biomarker | BIO-BCL2-EXPRESSION-IHC |
|---|---|
| Variant | BCL2 high expression by IHC |
| Disease | DIS-MCL |
| ESCAT tier | IIIA |
| Recommended combinations | venetoclax + ibrutinib (R/R MCL, off-label), venetoclax + acalabrutinib (trials) |
| Evidence summary | High BCL2 in MCL universal (cyclin D1-driven survival pathway). Venetoclax + ibrutinib (AIM trial; Tam NEJM 2018) active in R/R MCL — off-label. |
Notes
ESCAT IIIA.
Used By
No reverse references found in the YAML corpus.